Epidemiology and management of uterine fibroids.
Emma Giuliani, Sawsan As-Sanie, Erica E Marsh
https://pubmed.ncbi.nlm.nih.gov/31960950/Actively Recruiting
Led by Medstar Health Research Institute · Updated on 2025-06-29
50
Participants Needed
1
Research Sites
N/A
Total Duration
Researchers are evaluating the impact of uterine fibroids and fibroid surgery on the openness of fallopian tubes in women undergoing minimally invasive surgery. The study aims to understand if fibroids cause blockage of the fallopian tubes and how surgery to remove fibroids myomectomy affects this condition. This is important because open fallopian tubes are necessary for natural pregnancy, and current knowledge about how fibroids influence tubal function is limited. The study involves a procedure called chromopertubation, performed twice during planned laparoscopic or robotic myomectomy surgery. This procedure uses a dilute methylene blue dye injected into the uterus to see if the dye passes through the fallopian tubes, indicating whether they are open or blocked. Chromopertubation is done at the start and end of the surgery, taking less than 10 minutes in total. Researchers will record tubal patency and fibroid characteristics such as size, number, and location. Participants will be monitored for any adverse reactions during and after the surgery according to standard care. Data collected include tubal openness before and after surgery, fibroid details, and patient medical history. Follow-up includes a post-operative call to check on recovery. The primary outcome measured is the frequency of tubal occlusion before and after myomectomy, with no long-term follow-up planned. The total study participation coincides with the surgery and immediate recovery period.
CONDITIONS
Assessment of Tubal Occlusion During Minimally Invasive Myomectomy
A
Alexandra Snyder, MD
M
Mireille Truong, MD
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
Medstar Health Research Institute
Lead Sponsor
This table compares participation in this trial with other options available for this condition. The information is drawn from published research and the trial’s study details and is provided for educational purposes only.
| Factors | Chromopertubation (intraoperative) | Standard outpatient test (HSG or HyCoSy) |
|---|---|---|
| What it is | An intraoperative dye test using methylene blue during minimally invasive myomectomy to check tube openness | An outpatient imaging test such as HSG or HyCoSy used before surgery to non‑invasively assess whether fallopian tubes are open |
| Role in trial | Used as the diagnostic test during surgery for trial participants | Represents the usual preoperative test outside the study setting |
| Primary use | Determine tubal patency at the time of fibroid removal | Evaluate tubal openness before deciding further fertility management |
| How it is performed | Dye is instilled into the uterine cavity during minimally invasive myomectomy while observing spill through the tubes | Outpatient imaging with contrast or ultrasound to visualize tubal flow without surgery |
| Evidence status | Effectiveness for evaluating tubal patency is being assessed in this study; evidence not yet established | HSG and HyCoSy have moderate to high diagnostic accuracy and are widely used |
| Important safety risks | Potential allergy to methylene blue dye, including risk in G6PD deficiency or dye hypersensitivity | Procedures involve exposure to contrast or ultrasound; HSG includes radiation and contrast risks, HyCoSy avoids radiation |
| Important limitations | Only available intraoperatively during myomectomy; cannot be used for initial fertility workup | HSG may have false‑positive block rates and requires follow‑up laparoscopy; HyCoSy accuracy varies and requires specialized ultrasound |
Disclaimer: This comparison is created with the help of artificial intelligence(AI) and may contain errors or missing information. It is not medical advice and does not mean one option is better or safer than another. Clinical trials are still being studied, and joining a trial is your choice. Please consult your healthcare professional before making any decisions.
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person) for eligibility assessment prior to surgery
Duration - Day of surgery
Participants undergo minimally invasive myomectomy surgery with chromopertubation performed before and after the surgical procedure to assess tubal occlusion.
1 surgical visit including pre- and post-myomectomy chromopertubation procedures
Duration - 1 to 2 days
Participants are observed in the post-anesthesia care unit and contacted on post-operative day 1 to monitor for any adverse events following the surgery and chromopertubation procedures.
1 post-operative phone call or in-person assessment on Day 1 after surgery
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
DIAGNOSTIC
Number of Arms
1
Have more questions? Get in touch with our team for quick support
Emma Giuliani, Sawsan As-Sanie, Erica E Marsh
https://pubmed.ncbi.nlm.nih.gov/31960950/Saubhagya Kumar Jena, Sushree Samiksha Naik
https://pubmed.ncbi.nlm.nih.gov/31179795/Leonidas I Zepiridis, Grigoris F Grimbizis, Basil C Tarlatzis
https://pubmed.ncbi.nlm.nih.gov/26856931/Sadeghi Ramin, Fani Pakdel Azar, Hasanzadeh Malihe
https://pubmed.ncbi.nlm.nih.gov/21413854/Andrew W Horne, Hilary O D Critchley
https://pubmed.ncbi.nlm.nih.gov/17960533/Yurie Nako, Kuniaki Ota, Toshio Sujino...
https://pubmed.ncbi.nlm.nih.gov/39797266/Elizabeth A Pritts, William H Parker, David L Olive
https://pubmed.ncbi.nlm.nih.gov/18339376/Edgardo Somigliana, Marco Reschini, Valentina Bonanni...
https://pubmed.ncbi.nlm.nih.gov/33903032/A S Lev-Toaff, S Karasick, M E Toaff
https://pubmed.ncbi.nlm.nih.gov/8456668/Daniel Mayrhofer, John Preston Parry, Marlene Hager...
https://pubmed.ncbi.nlm.nih.gov/35807038/Medstar Health Research Institute
Lead Sponsor